Navigation Links
Tumor budding identified as predictor for unfavorable outcome in lung cancer
Date:8/31/2010

Lung cancer is the leading cause of cancer deaths worldwide, and the prognosis is generally poor, even if surgery is successful. Furthermore, the incidence of one type of lung cancer, adenocarcinoma, has been increasing in recent years. A better understanding of the changes in tumor cell biology that result in a more aggressive neoplastic phenotype (characteristic of an abnormal mass of tissue) that have been completely surgically removed may help identify patients at risk for recurrent disease and lead to the development of more effective therapeutic treatments. Tumor budding is one such characteristic that may provide insights on advancing the understanding of recurrence.

The term tumor budding refers to single cells or small clusters of up to four cells within the stromal tissue at the invasive margin of colorectal cancers. This morphologic feature is increasingly being recognized as an adverse prognostic factor. To progress in this understanding, a study featured in the September edition of the Journal of Thoracic Oncology (JTO) conducted the first study to evaluate tumor budding in adenocarcinoma of the lung.

In order to investigate the relationship between tumor budding and the prognostic significance, researchers reviewed the cases of 201 consecutive patients who had undergone complete resection of adenocarcinoma of the lung measuring ≤ 30 mm( 1.25 inches) in diameter. The presence of tumor budding was significantly associated with lymph node metastasis, pathologic stage, vascular invasion, lymphatic invasion, and pleural invasion. Furthermore, the overall five-year survival rates of the group with budding and the group without budding was 67.5 and 88.3 percent, respectively, and the difference was significant.

"Overall, the pilot study identified that tumor budding is a distinct morphologic feature that has biologic and prognostic significance; moreover, the presence was identified as a significant predictor of an unfavorable outcome," explained lead investigator, Yoko Yamaguchi, MD. "Justifiably, clarification of the molecular mechanism that causes budding in lung adenocarcinoma will be important in the future."


'/>"/>

Contact: Colleen Butz
cbutz@spectrumscience.com
202-587-2557
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation
2. With muscle-building treatment, mice live longer even as tumors grow
3. Lung stem cells vital to lung repair associated with poor cancer prognosis when found in tumor
4. A lethal brain tumors strength may be a weakness as well
5. Merlin protein found to control liver stem cells, prevent tumor development
6. New drug reduces tumor size in women with advanced hereditary ovarian or breast cancer
7. NIH award will enable design of brain tumor treatment that captures migrating cancer cells
8. New diagnostic chip able to generate single-cell molecular fingerprints for brain tumors
9. Iron oxide nanoparticles becoming tools for brain tumor imaging and treatment
10. LA Tumor Registry at LSUHSC awarded $12 million SEER contract by NCI
11. Key pathway in end-stage prostate cancer tumor progression blocked
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... Sandbox, one of ... to serve in the newly created position of executive vice president, chief creative ... efforts in the Chicago and LA offices. He reports to Nancy Finigan, president ...
(Date:5/3/2016)... ... May 03, 2016 , ... University of the ... the launch of its Associates and Bachelor's degrees in Health Studies. Leading figures ... University, Dr. Torsten N. Wiesel; Chairman and CEO of Fortune 500® company Henry ...
(Date:5/3/2016)... Toledo, OH (PRWEB) , ... May 03, 2016 , ... ... remain a leading cause of death across the United States and account for one ... physical and mental impairments or are permanently disabled. HCR ManorCare is launching a video ...
(Date:5/3/2016)... ... May 03, 2016 , ... For the sixth consecutive year, ... Technology (ICT) companies in the annual Branham300 listing. For 23 years, the Branhan300 ... ranked by revenue. , “We are honored to be on the Branham300 ...
(Date:5/3/2016)... ... May 03, 2016 , ... Branches, Inc. is proud to ... Climb children and youth programs in South Miami. Macy’s is a wonderful community partner ... Grow Program provides afterschool tutoring, mentoring, enrichment and academic support to elementary students 5 ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- According to market research "Global Magnetic ... Demand Forecast to 2022 - Industry Insights by Architecture ... High Field, Low to Mid Field, and Ultra High ... Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" P&S ... was valued at $5,351.7 million in 2015, and it ...
(Date:5/3/2016)... , May 3, 2016 ... Research Report provides a basic overview of the ... post which the surgical mesh report explores into ... Complete report on Surgical Mesh market ... and 98 tables and figures is available at ...
(Date:5/2/2016)... 2016  Deerfield announced today it led the ... Inc. Graybug Vision is an early stage pharmaceutical ... care for ocular diseases including wet age-related macular ... first developed at Johns Hopkins University and has ... Graybug Vision is developing ophthalmology products ...
Breaking Medicine Technology: